India-based Cipla has introduced Serroflo (salmeterol/fluticasone MDI) in Germany and Sweden to treat patients suffering from asthma.
Serroflo is expected to improve the affordability of fixed combinations in Europe and help manage health costs for respiratory treatment.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
Cipla Europe head Frank Pieters said: "With Serroflo, we offer in Germany and Sweden an alternative, which is effective and efficient and therefore brings many advantages into a market, which suffers from limited resources."
The new product is available under the name Serroflo in Germany, while it is introduced as Salmeterol/Fluticasone Cipla in Sweden.
Both are available in a pMDI with HFA propellant in two strengths, 120 doses of 25/125mcg salmeterol/fluticasone and 120 doses of 25/250mcg salmeterol/fluticasone.
The combination is already available under the name Duohal in Europe, apart from Croatia.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataCipla managing director and global CEO Subhanu Saxena said: "Over the next 12-18 months we will see a series of launches throughout Europe as we know that there is a common need for high quality, affordable, reliable and thus sustainable therapy-alternatives."
As per the ERS Lung white book 2013, around 30 million people under 45 years suffer from asthma in Europe.
Cipla produces around 2,000 products in 65 therapeutic categories and sells its products in approximately 100 countries.
